Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53

被引:29
作者
Kichina, JV
Rauth, S
Das Gupta, TK
Gudkov, AV
机构
[1] Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA
[2] Univ Illinois, Dept Surg Oncol, Chicago, IL USA
关键词
melanoma; p53; Ing1; tumor suppressor; transactivation;
D O I
10.1038/sj.onc.1206741
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Malignant melanomas are frequently characterized by elevated levels of wild-type p53, suggesting that p53 function could be suppressed by a mechanism different from p53 mutation. We analysed the functionality of the p53-signaling pathway in a panel of seven human melanoma cell lines consisting of one p53-deficient line, two lines with mutant p53, and four lines expressing wildtype p53. Only lines with wild-type p53 were characterized by elevated levels of endogenous p21, high activity of p53-responsive reporters and accumulation of p53 in response to genotoxic stress, common properties of functional p53. The presence of wild-type p53 was associated with depletion or loss of p14(ARF) and p16 expression. The levels of p33(ING1b) and p24(ING1c), two major products of Ing1 locus and putative coregulators of p53, were elevated in all cell lines tested; however, ectopic expression of either ING1 isoform had no effect on cell proliferation. All lines retained expression of Apaf-1, and all but one remained sensitive to ectopic expression of retrovirus-transduced p53. Our data indicate that regardless of abnormally high levels of p53 in melanomas, their p53 remains competent in transactivation of its targets, and, if highly overexpressed, capable of growth inhibition. Hence, the p53 pathway in malignant melanomas can be considered for pharmacological targeting and anticancer gene therapy.
引用
收藏
页码:4911 / 4917
页数:7
相关论文
共 53 条
[21]   A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY UTILIZING P53 AND GADD45 IS DEFECTIVE IN ATAXIA-TELANGIECTASIA [J].
KASTAN, MB ;
ZHAN, QM ;
ELDEIRY, WS ;
CARRIER, F ;
JACKS, T ;
WALSH, WV ;
PLUNKETT, BS ;
VOGELSTEIN, B ;
FORNACE, AJ .
CELL, 1992, 71 (04) :587-597
[22]   IDENTIFICATION OF P53 AS A SEQUENCE-SPECIFIC DNA-BINDING PROTEIN [J].
KERN, SE ;
KINZLER, KW ;
BRUSKIN, A ;
JAROSZ, D ;
FRIEDMAN, P ;
PRIVES, C ;
VOGELSTEIN, B .
SCIENCE, 1991, 252 (5013) :1708-1711
[23]   Tumor suppressor p53 down-regulates tissue-specific expression of tyrosinase gene in human melanoma cell lines [J].
Kichina, J ;
Green, A ;
Rauth, S .
PIGMENT CELL RESEARCH, 1996, 9 (02) :85-91
[24]  
Leung KM, 2002, CANCER RES, V62, P4890
[25]   Immunohistochemical study of 49 cutaneous melanomas: p53, PCNA, Bcl-2 expression and multidrug resistance [J].
Loggini, B ;
Rinaldi, I ;
Pingitore, R ;
Cristofani, R ;
Castagna, M ;
Barachini, P .
TUMORI, 2001, 87 (03) :179-186
[26]   PRIMARY STRUCTURE POLYMORPHISM AT AMINO-ACID RESIDUE-72 OF HUMAN-P53 [J].
MATLASHEWSKI, GJ ;
TUCK, S ;
PIM, D ;
LAMB, P ;
SCHNEIDER, J ;
CRAWFORD, LV .
MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (02) :961-963
[27]   In vitro transformation of human congenital naevus to malignant melanoma [J].
Mehta, RR ;
Bratescu, L ;
Graves, JM ;
Shilkaitis, A ;
Green, A ;
Mehta, RG ;
Das Gupta, TK .
MELANOMA RESEARCH, 2002, 12 (01) :27-33
[28]   THE TRANSCRIPTIONAL TRANSACTIVATION FUNCTION OF WILD-TYPE-P53 IS INHIBITED BY SV40 LARGE T-ANTIGEN AND BY HPV-16 E6-ONCOPROTEIN [J].
MIETZ, JA ;
UNGER, T ;
HUIBREGTSE, JM ;
HOWLEY, PM .
EMBO JOURNAL, 1992, 11 (13) :5013-5020
[29]  
Moll UM, 1996, MOL CELL BIOL, V16, P1126
[30]  
MONTANO X, 1994, ONCOGENE, V9, P1455